Functional aspects of cellular micro-compartmentation in the development of neurodegenaration: Mutation induced aberrant protein-protein associations

Molecular and Cellular Biochemistry

Volumn 256-257, Issue 1-2, 2004, Pages 83-93

  Ovádi, Judith ^a   Orosz, Ferenc ^a   Hollán, Susan ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Central Institute   (Hungary)

Author keywords

Glycolysis; Microtubule; Misfolding; Mutation; Neurodegeration; Protein protein interaction

Indexed keywords

GLYCOLYTIC ENZYME; MUTANT PROTEIN; TRIOSEPHOSPHATE ISOMERASE;

ALZHEIMER DISEASE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL STRUCTURE; CYTOSKELETON; DISEASE COURSE; ENZYME DEFICIENCY; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; INBORN ERROR OF METABOLISM; MUTATION; NERVE DEGENERATION; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; SENILE PLAQUE; SYMPTOMATOLOGY;

EID: 0842323764     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/b:mcbi.0000009860.86969.72     Document Type: Review

References (79)

1. Baines W: The parts list of life. Nat Biotechnol 19: 401-402, 2001
2. Raamsdonk LM, Teusink B, Broadhuist D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ et al.: A functional genomics strategy hat uses metabolom data to reveal the phenotype of silent mutations. Nat Biotechnol 19: 45-50, 2001
3. Brady ST: Axonal transport of glycolytic enzymes: Aldolase and pyruvate kinase. Trans Am Soc Neurochem 13: 226, 1982
4. Oblinger MM, Foe LG, Kwiatkowska D, Kemp RG: Phosphofructokinase in the rat nervous system: Regional differences in activity and characteristics of axonal transport. J Neurosci Res 21: 25-34, 1988
5. Wágner G, Kovács J, Lôw P, Orosz F, Ovádi J: Tubulin and microtubule are potential targets for brain hexokinase binding. FEBS Lett 509: 81-84, 2001
6. Lehotzky A, Telegdi M, Liliom K, Ovádi J: Interaction of phosphofructokinase with tubulin and microtubule: Quantitative evaluation of the mutual effects. J Biol Chem 268: 10888-10894, 1993
7. Orosz F, Santamaría B, Ovádi J, Aragón JJ: Phosphofructokinase from Dictyostelium discoideum is a potent inhibitor of tubulin polymerization. Biochemistry 38: 1857-1865, 1999
8. Vértessy GB, Bánkfalvi D, Kovács J, Lôv P, Lehotzky A, Ovádi J: Pyruvate kinase as a microtubule destabilizing factor in vitro. Biochem Biophys Res Commun 254: 430-435, 1999
9. Ovádi J, Orosz F: Calmodulin and dynamics of interactions of cytosolic enzymes. Curr Top Cell Regul 33: 105-126, 1992
10. Vértessy GB, Orosz F, Kovács J, Ovádi J: Alternative binding of two sequential glycolytic enzymes to microtubules: Molecular studies in phosphofructokinase/aldolase/microtubule system. J Biol Chem 272: 25542-25546, 1997
11. Lehotzky A, Pálfia Z, Kovács J, Molnár A, Ovádi J: Ligand-modulated cross-bridging of microtubules by phosphofructokinase. Biochem Biophys Res Commun 204: 585-591, 1994
12. Minton AP: The effect of volume occupancy upon the thermodynamic activity of proteins: Some biochemical consequences. Mol Cell Biochem 55: 119-140, 1983
13. Ellis RJ: Macromolecular crowding: Obvious but underappreciated. Trends Biochem Sci 26: 597-604, 2001
14. Srere PA: Why are enzymes so big? Trends Biochem Sci 9: 387-390, 1984
15. Ovádi J, Vértessy BG, Kovács J, Wágner G, Liliom K, Orosz F: Interrelationship of cytoarchitecture and glucose metabolism. In: E. Wagner, J. Normann et al. (eds). From Symbiosis to Eukaryotism - Endocytobiology VII. Geneva University Press, Geneva, 1999, pp 517-532
16. Vértessy BG, Kovács J, Ovádi J: Specific characteristics of phosphofructokinase-microtubule interaction. FEBS Lett 379: 191-195, 1996
17. Lee JC, Hesterberg LK, Luther MA, Cai G-Z: Rabbit muscle phosphofructokinase. In: G. Herve (ed). Allosteric Enzymes. CRC Press, Boca Raton, 1989, pp 231-254
18. Martínez-Costa OH, Estévez AM, Sanchez V, Aragón JJ: Purification and properties of phosphofructokinase from Dictyostelium discoideum. Eur J Biochem 226: 1007-1017, 1994
19. Liliom K, Wágner G, Kovács J, Comin B, Cascante M, Orosz F, Ovádi J: Combined enhancement of microtubule assembly and glucose metabolism in neuronal systems in vitro. Decreased sensitivity to copper toxicity. Biochem Biophys Res Commun 264: 605-610, 1999
20. Liliom K, Wágner G, Pácz A, Cascante M, Kovács J, Ovádi J: Organization-dependent effects of toxic bivalent ions: Microtubule assembly and glycolysis. Eur J Biochem 267: 4731-4739, 2000
21. Wágner G, Liliom K, Oláh J, Orosz F, Ovádi J: Supramolecular organization-dependent responses to stimuli. In: J.-H.S. Hofmeyr, J.M. Rohwer, J.L. Snoep (eds). BioThermoKinetics2000: Animating the Cellular Map. Stellenbosch University Press, Stellenbosch, 2000, pp 177-180
22. Hlavanda E, Kovács J, Oláh J, Orosz F, Medzihradszky KF, Ovádi J: Brain-specific p25 protein binds to tubulin an microtubule and induces aberrant microtubule assemblies at substoichiometric concentration. Biochemistry 41: 8657-8664, 2002
23. Takahashi M, Tomizawa K, Ishiguro K, Sato K, Omori A, Sato S, Shiratsuchi A, Uchida T, Imahori K: A novel brain-specific 25 kDa protein (p25) is phosphorylated by a Ser/Thr-Pro kinase (TPK II) from tau protein kinase fractions. FEBS Lett 289: 37-43, 1991
24. Seki N, Hattori A, Sugano S, Suzuki Y, Nakagawara A, Muramatsu M, Hori T, Saito T: A novel human gene whose product shares significant homology with the bovine brain-specific protein p25 on chromosome 5p15.3. J Hum Genet 44: 121-122, 1999
25. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai L-H: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622, 1999
26. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275: 17166-17172, 2000
27. Unger E, Böhm KJ, Müller H, Grossmann H, Fenske H, Vater W: Formation of double-walled and multilayered tubulin sheets by basic proteins. Eur J Cell Biol 46: 98-104, 1988
28. Bates GP, Mangiarini L, Mahal A, Davies SW: Transgenic models of Huntington's disease. Hum Mol Genet 6: 1633-1637, 1997
29. Ross CA: When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 15: 493-496, 1995
30. Perutz MF: Glutamine repeats and inherited neurodegenerative diseases: Molecular aspects. Curr Opin Struct Biol 6: 848-858, 1996
31. Caughey B, Chesebro B: Prion protein and the transmissible spongioform encephalopathies. Trends Cell Biol 7: 56-62, 1997
32. Kahlem P, Green H, Djian P: Transglutaminase action initiates Huntington's disease: Selective polymerization of huntingtin containing expanded polyglutamine. Mol Cell 1: 595-601, 1998
33. Tukamoto T, Nukina N, Ide K, Kanazawa I: Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Mol Brain Res 51: 8-14, 1997
34. Gutekunst C-A, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, Hersch SM: Identification and localization of huntingtin in brain and human lymhoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci USA 92: 8710-8714, 1995
35. Burke JR, Enghild JJ, Martin ME, Jou Y-S, Myers RM, Roses AD, Vance JM, Strittmatter WJ: Huntington and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med 2: 347-350, 1996
36. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, Zoghbi HY: Spinocerebellar ataxin type-1 and spinobullar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet 5: 1311-1318, 1996
37. Barinaga M: An intriguing new lead on Huntington's disease. Science 271: 1233-1234, 1996
38. Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Blass JP: Glyceraldehyde-3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Dev Neurosci 20: 462-468, 1998
39. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonstattel JP, Carraway R, Reeves SA et al.: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat neurons. Neuron 94: 1075-1081, 1995
40. Sharp AH, Lowv SJ, Li SH, Li XJ, Bao J, Waster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J et al.: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14: 1065-1074, 1995
41. Trottier Y Devys D, Imbert G, Saudou F, An I, Lutz I, Weber Ch, Agid Y, Hirsch EC, Mandel JL: Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated forms. Nat Genet 10: 104-110, 1995
42. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW et al.: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotypes in transgenic mice. Cell 87: 493-506, 1996
43. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J et al.: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity and selective striatal neurodegneration. Neuron 23: 181-192, 1999
44. Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W: Calsenilin, a calcium binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat Med 4: 1177-1181, 1998
45. Cha HJ: Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23: 387-392, 2000
46. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G et al.: Decreased expression of striatal signaling genes ina mouse model of Huntington's disease. Hum Mol Genet 9: 1259-1271, 2000
47. Tabaton M: Research advances in the biology of Alzheimer's disease. Clin Geriatr Med 10: 249-255, 1994
48. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706, 1991
49. Meier-Ruge WA, Bertoni-Freddari C: Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann NY Acad Sci 826: 229-241, 1997
50. Schulze H, Schuyler A, Stuber D, Dobeli H, Langen H, Huber G: Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's β-amyloid precursor protein. J Neurochem 60: 1915-1922, 1993
51. Nagy E, Rigby WF: Glyceraldehyde-3-phosphate dehydrogenase selectively binds AT-rich RNA in the NAD(+)-binding region (Rossmann fold). J Biol Chem 270: 2755-2763, 1995
52. Durrieu C, Bernier-Valentin F, Rousset B: Microtubules bind glyceraldehyde 3-phosphate dehydrogenase and modulate its enzyme activity and quaternary structure. Arch Biochem Biophys 252: 32-40, 1987
53. Sokoloff L: Cerebral circulatory and metabolic changes associated with aging. Res Publ Assoc Res Nerv Ment Dis 41: 237-254, 1966
54. Duara R, Grady C, Haxby J, Sundaram M, Cutler N, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI: Positron emission tomography in Alzheimer's disease. Neurology 36: 879-887, 1986
55. Tucek S, Ricny J, Dolezal V: Advances in the biology of cholinergic neurons. Adv Neurol 51: 109-115, 1990
56. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K: Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 93: 2719-2723, 1996
57. Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K. Hoshino T, Imahori K: Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem 272: 2038-2041, 1997
58. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL: D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 97: 5440-5444, 2000
59. Strohman R: Maneuvering in the complex path from genotype to phenotype. Science 296: 701-703, 2002
60. Bigl M, Brückner MK, Arendt T, Bigl V, Eschirch K: Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 106: 499-511, 1999
61. Schneider AS: Triosephosphate isomerase deficiency: historical perspectives and molecular aspects. Bailliére's Clin Haematol 13: 119-140, 2000
62. Tanaka KR, Zerez CR: Red cell enzymopathies of the glycolytic pathway. Semin Hematol 27: 165-185, 1990
63. Chang M-L, Artymiuk PJ, Wu X, Hollán S, Lammi A, Maquat LE: Human triosephosphate isomerase deficiency resulting from mutation of Phe-240. Am J Hum Genet 52: 1260-1269, 1993
64. Valentin C, Cohen-Solal M, Maquat L, Horányi M, Inselt-Kovács M, Hollán S: Identical germ-line mutations in the triosephosphate isomerase alleles of two brothers associated with distinct clinical phenotypes. CR Acad Sci III 323: 245-250, 2000
65. Orosz F, Oláh J, Alvarez M, Keserû GM, Szabó B, Wágner G, Kovári Z, Horányi M, Baróti K, Martial JA et al.: Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency. Blood 98: 3106-3112, 2001
66. Oláh J, Orosz F, Keserû GM, Kovári Z, Kovács, J, Hollán S, Ovádi J: Triosephosphate isomerase deficiency: A neurodegenerative misfolding disease. Biochem Soc Trans 30: 30-38, 2002
67. Orosz F, Wágner G, Liliom K, Kovács J, Baróti K, Horányi M, Farkas T, Hollán S, Ovádi J: Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc Natl Acad Sci USA 97: 1026-1031, 2000
68. Hollán S, Fujii H, Hirono A, Hirono K, Karro H, Miwa S, Harsanyi V, Gyodi E, Inselt-Kovacs M: Hereditary triosephosphate isomerase (TPI) deficiency: Two severaly affected brothers one with and one without neurological symptoms. Hum Genet 92: 486-490, 1993
69. Hollán S, Dey I, Szollár L, Horányi M, Magócsi M, Harsányi V, Farkas T: Erythrocyte lipids in triose-phosphate isomerase deficiency. Proc Natl Acad Sci USA 92: 268-271, 1995
70. Hollán S, Magócsi M, Fodor E, Horányi M, Harsányi V, Farkas T: Search for the pathogenesis of the differing phenotype in two compound heterozygote Hungarian brothers with the same genotypic triosephosphate isomerase deficiency. Proc Natl Acad Sci USA 94: 10362-10366, 1997
71. Karg E, Németh I, Horányi M, Pintér S, Vécsei L, Hollán S: Diminished blood levels of reduced glutathione and -tocopherol in triosephosphate isomerase deficient brothers. Blood Cells Mol Dis 26: 91-100, 2000
72. Lohner K: Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Chem Phys Lipids 81: 167-184, 1996
73. Lansbury PT: Structural neurology: Are seeds at the root of neuronal degeneration. Neuron 19: 1151-1154, 1997
74. Davies SW, Trumaine M, Cozens BA, Di Figlia M, Sharp AH, Ross GA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548, 1997
75. Price DL, Sisodia SS, Borchelt DR: Genetic neurodegenerative diseases: The human illness and transgenic models. Science 292: 1079-1083, 1998
76. Scherzinger E, Lurz R, Tourmaine M, Mangiarini L, Hollenbach B, Hasenbeck R, Bates GP, Davies SW, Lahrach H, Wanker EE: Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549-558, 1997
77. Volker KW, Knull HR: A glycolytic enzyme binding domain in tubulin. Arch Biochem Biophys 238: 237-243, 1997
78. Marmillot P, Keith T, Srivastava DK, Knull HR: Effect of tubulin on the activity of the muscle isoenzyme of lactate dehyrogenase. Arch Biochem Biophys 315: 467-472, 1994
79. Mande SC, Mainfroid V, Kalk KH, Goraj K, Martial JA, Hol WGJ: Crystal structure of recombinant human triosephosphate isomerase at 2.8 Å resolution. Triosephosphate isomerase-related human genetic disorders and comparison with the trypanosomal enzyme. Prot Sci 3: 810-821, 1994